1. Urinary kallidinogenase for the treatment of cerebral arterial stenosis.
- Author
-
Zhao L, Zhao Y, Wan Q, and Zhang H
- Subjects
- Adult, Aged, Aged, 80 and over, Amyloid beta-Peptides blood, Arterial Occlusive Diseases blood, Arterial Occlusive Diseases diagnosis, Arterial Occlusive Diseases psychology, Biomarkers blood, Cerebral Arterial Diseases blood, Cerebral Arterial Diseases diagnosis, Cerebral Arterial Diseases psychology, China, Cognition drug effects, Constriction, Pathologic, Female, Humans, Male, Middle Aged, Peptide Fragments blood, Tissue Kallikreins adverse effects, Treatment Outcome, Arterial Occlusive Diseases drug therapy, Cerebral Arterial Diseases drug therapy, Tissue Kallikreins therapeutic use
- Abstract
Aim: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis., Methods: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment., Results: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment., Conclusion: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis.
- Published
- 2015
- Full Text
- View/download PDF